Althea Technologies, Inc.
http://www.altheatech.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Althea Technologies, Inc.
And They’re Off! First Stelara Biosimilar Enters European Markets
Stada and Alvotech have heralded the start of biosimilar competition to Stelara in Europe with the launch of their partnered Uzpruvo version.
After Denosumab Deals, Alvotech Lines Up Filings
Following positive clinical trial results for its AVT03 proposed denosumab biosimilar to Prolia/Xgeva, Alvotech is planning filings in “major global markets.” Launches are expected to follow through recently-agreed partnerships.
Deal Watch: Lilly Partners With OpenAI On Drug-Resistant Pathogens
Plus transactions involving ANI/Alimera, Gilead/ashibio, Sanofi/Belharra and more.
Finance Watch: SPACs Attempt A Comeback Ahead Of Full IPO Recovery
Public Company Edition: Several special purpose acquisition corporations have emerged, including various health care- and life science-focused SPACs. Also, Alvotech entered into a $965m refinancing agreement and Avidity grossed $461m in a follow-on offering, among other updates.
Company Information
- Other Names / Subsidiaries
-
- Altus Pharmaceuticals Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice